Management of patients after endovascular interventions for peripheral artery disease

Circulation

Volumn 128, Issue 7, 2013, Pages 749-757

  Sobieszczyk, Piotr ^a   Eisenhauer, Andrew ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Endovascular procedures; Peripheral arterial disease

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; CLOPIDOGREL; PRASUGREL; PROBUCOL; RAPAMYCIN; TICAGRELOR;

ANTICOAGULANT THERAPY; ARTICLE; BARE METAL STENT; BLEEDING; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; DRUG ELUTING STENT; DRUG INDUCED DISEASE; DRUG SAFETY; ENDOVASCULAR SURGERY; HUMAN; IN-STENT RESTENOSIS; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTENOSIS; SELF EXPANDING STENT;

ENDOVASCULAR PROCEDURES; PERIPHERAL ARTERIAL DISEASE;

AFTERCARE; ANGIOPLASTY, BALLOON; ANKLE BRACHIAL INDEX; ASPIRIN; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; CONSTRICTION, PATHOLOGIC; DISEASE MANAGEMENT; ENDOVASCULAR PROCEDURES; FEMORAL ARTERY; FIBRINOLYTIC AGENTS; HUMANS; PERIPHERAL ARTERIAL DISEASE; PHYSICAL EXAMINATION; PLATELET AGGREGATION INHIBITORS; POPLITEAL ARTERY; POSTOPERATIVE CARE; RECURRENCE; STENTS; TETRAZOLES; ULTRASONOGRAPHY, DOPPLER, DUPLEX; VASCULAR PATENCY;

EID: 84882249073     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.113.001560     Document Type: Article

References (53)

1. Rowe VL, Lee W, Weaver FA, Etzioni D. Patterns of treatment for peripheral arterial disease in the United States: 1996-2005. J Vasc Surg. 2009;49:910-917.
2. Schillinger M, Minar E. Percutaneous treatment of peripheral artery disease: Novel techniques. Circulation. 2012;126:2433-2440.
3. Berger JS, Hiatt WR. Medical therapy in peripheral artery disease. Circulation. 2012;126:491-500.
4. Kruidenier LM, Nicolaï SP, Rouwet EV, Peters RJ, Prins MH, Teijink JA. Additional supervised exercise therapy after a percutaneous vascular intervention for peripheral arterial disease: A randomized clinical trial. J Vasc Interv Radiol. 2011;22:961-968.
5. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hiratzka LF, Murphy WR, Olin JW, Puschett JB, Rosenfield KA, Sacks D, Stanley JC, Taylor LM Jr, White CJ, White J, White RA, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B; American Association for Vascular Surgery/Society for Vascular Surgery; Society for Cardiovascular Angiography and Interventions; Society for Vascular Medicine and Biology; Society of Interventional Radiology; ACC/AHA Task Force on Practice Guidelines. ACC/AHA guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): A collaborative report from the American Associations for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): Summary of recommendations. J Vasc Interv Radiol. 2006;17:1383-1397.
6. Rooke TW, Hirsch AT, Misra S, Sidawy AN, Beckman JA, Findeiss LK, Golzarian J, Gornik HL, Halperin JL, Jaff MR, Monet GL, Olin JW, Stanley JC, White CJ, White JV, Zierler R, Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hiratzka LF, Murphy WR, Olin JW, Puschett JB, Rosenfield KA, Sacks D, Stanley JC, Taylor LM Jr, White CJ, White JV, White RA, Jacobs AK, Anderson JL, Albert N, Creager MA, Ettinger SM, Guyton RA, Halperin JL, Hochman JS, Kushner FG, Magnus Ohman E, Stevenson W, Yancy CW. 2011 ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;124:2020-2045.
7. Tendera M, Aboyans V, Bartelink ML, Baumgartner I, Clément D, Collet JP, Cremonesi A, De Carlo M, Erbel R, Fowkes FG, Heras M, Kownator S, Minar E, Ostergren J, Poldermans D, Riambau V, Roffi M, Röther J, Sievert H, van Sambeek M, Zeller T; ESC Committee for Practice Guidelines. ESC guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: The Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J. 2011;32:2851-2906.
8. Dotter CT, Judkins MP. Transluminal treatment of arteriosclerotic obstruction: Description of a new technic and a preliminary report of its application. Circulation. 1964;30:654-670.
9. Dotter CT, Rösch J, Anderson JM, Antonovic R, Robinson M. Transluminal iliac artery dilatation. Nonsurgical catheter treatment of atheromatous narrowing. JAMA. 1974;230:117-124.
10. Wierny L, Plass R, Porstmann W. Long-term results in 100 consecutive patients treated by transluminal angioplasty. Radiology. 1974;112:543-548.
11. Zeitler E. Percutaneous dilatation and recanalization of iliac and femoral arteries. Cardiovasc Intervent Radiol. 1980;3:207-212.
12. Martin EC, Fankuchen EI, Karlson KB, Dolgin C, Collins RH, Voorhees AB Jr, Casarella WJ. Angioplasty for femoral artery occlusion: Comparison with surgery. AJR Am J Roentgenol. 1981;137:915-919.
13. Hewes RC, White RI Jr, Murray RR, Kaufman SL, Chang R, Kadir S, Kinnison ML, Mitchell SE, Auster M. Long-term results of superficial femoral artery angioplasty. AJR Am J Roentgenol. 1986;146:1025-1029.
14. Werk M, Langner S, Reinkensmeier B, Boettcher HF, Tepe G, Dietz U, Hosten N, Hamm B, Speck U, Ricke J. Inhibition of restenosis in femoropopliteal arteries: Paclitaxel-Coated Versus Uncoated Balloon: Femoral Paclitaxel Randomized pilot trial. Circulation. 2008;118:1358-1365.
15. Micari A, Cioppa A, Vadalà G, Castriota F, Liso A, Marchese A, Grattoni C, Pantaleo P, Cremonesi A, Rubino P, Biamino G. Clinical evaluation of a paclitaxel-eluting balloon for treatment of femoropopliteal arterial disease: 12-month results from a multicenter Italian registry. JACC Cardiovasc Interv. 2012;5:331-338.
16. Laird JR, Katzen BT, Scheinert D, Lammer J, Carpenter J, Buchbinder M, Dave R, Ansel G, Lansky A, Cristea E, Collins TJ, Goldstein J, Jaff MR; RESILIENT Investigators. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: Twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv. 2010;3:267-276.
17. Schillinger M, Sabeti S, Dick P, Amighi J, Mlekusch W, Schlager O, Loewe C, Cejna M, Lammer J, Minar E. Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. Circulation. 2007;115:2745-2749.
18. Krankenberg H, Schlüter M, Steinkamp HJ, Bürgelin K, Scheinert D, Schulte KL, Minar E, Peeters P, Bosiers M, Tepe G, Reimers B, Mahler F, Tübler T, Zeller T. Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: The Femoral Artery Stenting Trial (FAST). Circulation. 2007;116:285-292.
19. Duda SH, Pusich B, Richter G, Landwehr P, Oliva VL, Tielbeek A, Wiesinger B, Hak JB, Tielemans H, Ziemer G, Cristea E, Lansky A, Bérégi JP. Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: Six-month results. Circulation. 2002;106:1505-1509.
20. Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB, Zeller T, Roubin GS, Burket MW, Khatib Y, Snyder SA, Ragheb AO, White JK, Machan LS; Zilver PTX Investigators. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: Twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv. 2011;4:495-504.
21. Yokoi H, Daida H, Kuwabara Y, Nishikawa H, Takatsu F, Tomihara H, Nakata Y, Kutsumi Y, Ohshima S, Nishiyama S, Seki A, Kato K, Nishimura S, Kanoh T, Yamaguchi H. Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: The Probucol Angioplasty Restenosis Trial. J Am Coll Cardiol. 1997;30:855-862.
22. Tardif JC, Cöté G, Lespérance J, Bourassa M, Lambert J, Doucet S, Bilodeau L, Nattel S, de Guise P. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty: Multivitamins and Probucol Study Group. N Engl J Med. 1997;337:365-372.
23. Gallino A, Do DD, Alerci M, Baumgartner I, Cozzi L, Segatto JM, Bernier J, Tutta P, Kellner F, Triller J, Schneider E, Amann-Vesti B, Studer G, Jäger K, Aschwanden M, Canevascini R, Jacob AL, Kann R, Greiner R, Mahler F. Effects of probucol versus aspirin and versus brachytherapy on restenosis after femoropopliteal angioplasty: The PAB randomized multicenter trial. J Endovasc Ther. 2004;11:595-604.
24. Kufner S, Hausleiter J, Ndrepepa G, Schulz S, Bruskina O, Byrne RA, Fusaro M, Kastrati A, Schömig A, Mehilli J; OSIRIS Trial Investigators. Long-term risk of adverse outcomes and new malignancies in patients treated with oral sirolimus for prevention of restenosis. JACC Cardiovasc Interv. 2009;2:1142-1148.
25. Hausleiter J, Kastrati A, Mehilli J, Vogeser M, Zohlnhöfer D, Schühlen H, Goos C, Pache J, Dotzer F, Pogatsa-Murray G, Dirschinger J, Heemann U, Schömig A; OSIRIS Investigators. Randomized, double-blind, placebocontrolled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: The Oral Sirolimus to Inhibit Recurrent In-Stent Stenosis (OSIRIS) trial. Circulation. 2004;110:790-795.
26. Rodriguez AE, Granada JF, Rodriguez-Alemparte M, Vigo CF, Delgado J, Fernandez-Pereira C, Pocovi A, Rodriguez-Granillo AM, Schulz D, Raizner AE, Palacios I, O'Neill W, Kaluza GL, Stone G; ORAR II Investigators. Oral rapamycin after coronary bare-metal stent implantation to prevent restenosis: The Prospective, Randomized Oral Rapamycin in Argentina (ORAR II) Study. J Am Coll Cardiol. 2006;47:1522-1529.
27. Waksman R, Ajani AE, Pichard AD, Torguson R, Pinnow E, Canos D, Satler LF, Kent KM, Kuchulakanti P, Pappas C, Gambone L, Weissman N, Abbott MC, Lindsay J; Oral Rapamune to Inhibit Restenosis Study. Oral rapamycin to inhibit restenosis after stenting of de novo coronary lesions: The Oral Rapamune to Inhibit Restenosis (ORBIT) study. J Am Coll Cardiol. 2004;44:1386-1392.
28. Iida O, Nanto S, Uematsu M, Morozumi T, Kitakaze M, Nagata S. Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions. J Vasc Surg. 2008;48:144-149.
29. Soga Y, Yokoi H, Kawasaki T, Nakashima H, Tsurugida M, Hikichi Y, Nobuyoshi M. Efficacy of cilostazol after endovascular therapy for femoropopliteal artery disease in patients with intermittent claudication. J Am Coll Cardiol. 2009;53:48-53.
30. Iida O, Nanto S, Uematsu M, Ikeoka K, Okamoto S, Dohi T, Fujita M, Nagata S. Long-term results of endovascular therapy with nitinol stent implantation for TASC II A/B femoro-popliteal artery lesions: 4 years' experience. Circ J. 2009;73:2143-2147.
31. Soga Y, Iida O, Hirano K, Yokoi H, Nanto S, Nobuyoshi M. Mid-term clinical outcome and predictors of vessel patency after femoropopliteal stenting with self-expandable nitinol stent. J Vasc Surg. 2010;52:608-615.
32. Soga Y, Iida O, Hirano K, Suzuki K, Yokoi H, Nobuyoshi M. Restenosis after stent implantation for superficial femoral artery disease in patients treated with cilostazol. Catheter Cardiovasc Interv. 2012;79:541-548.
33. Kinlay S. Outcomes for clinical studies assessing drug and revascularization therapies for claudication and critical limb ischemia in peripheral artery disease. Circulation. 2013;127:1241-1250.
34. Bergamini TM, George SM Jr, Massey HT, Henke PK, Klamer TW, Lambert GE, Miller FB, Garrison RN, Richardson JD. Intensive surveillance of femoropopliteal-tibial autogenous vein bypasses improves longterm graft patency and limb salvage. Ann Surg. 1995;221:507-515.
35. Davies AH, Hawdon AJ, Sydes MR, Thompson SG; VGST Participants. Is duplex surveillance of value after leg vein bypass grafting? Principal results of the Vein Graft Surveillance Randomised Trial (VGST). Circulation. 2005;112:1985-1991.
36. Connors G, Todoran TM, Engelson BA, Sobieszczyk PS, Eisenhauer AC, Kinlay S. Percutaneous revascularization of long femoral artery lesions for claudication: Patency over 2.5 years and impact of systematic surveillance. Catheter Cardiovasc Interv. 2011;77:1055-1062.
37. Todoran TM, Connors G, Engelson BA, Sobieszczyk PS, Eisenhauer AC, Kinlay S. Femoral artery percutaneous revascularization for patients with critical limb ischemia: Outcomes compared to patients with claudication over 2.5 years. Vasc Med. 2012;17:138-144.
38. Vroegindeweij D, Tielbeek AV, Buth J, Vos LD, van den Bosch HC. Patterns of recurrent disease after recanalization of femoropopliteal artery occlusions. Cardiovasc Intervent Radiol. 1997;20:257-262.
39. Aboyans V, Criqui MH, Abraham P, Allison MA, Creager MA, Diehm C, Fowkes FG, Hiatt WR, Jönsson B, Lacroix P, Marin B, McDermott MM, Norgren L, Pande RL, Preux PM, Stoffers HE, Treat-Jacobson D; American Heart Association Council on Peripheral Vascular Disease; Council on Epidemiology and Prevention; Council on Clinical Cardiology; Council on Cardiovascular Nursing; Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia. Measurement and interpretation of the ankle-brachial index: A scientific statement from the American Heart Association. Circulation. 2012;126:2890-2909.
40. Baril DT, Rhee RY, Kim J, Makaroun MS, Chaer RA, Marone LK. Duplex criteria for determination of in-stent stenosis after angioplasty and stenting of the superficial femoral artery. J Vasc Surg. 2009;49:133-138.
41. Ranke C, Creutzig A, Alexander K. Duplex scanning of the peripheral arteries: Correlation of the peak velocity ratio with angiographic diameter reduction. Ultrasound Med Biol. 1992;18:433-440.
42. Schlager O, Francesconi M, Haumer M, Dick P, Sabeti S, Amighi J, Mlekusch W, Koppensteiner R, Minar E, Schillinger M. Duplex sonography versus angiography for assessment of femoropopliteal arterial disease in a "real-world" setting. J Endovasc Ther. 2007;14:452-459.
43. Schillinger M, Sabeti S, Loewe C, Dick P, Amighi J, Mlekusch W, Schlager O, Cejna M, Lammer J, Minar E. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 2006;354:1879-1888.
44. Zeller T, Dake MD, Tepe G, Brechtel K, Noory E, Beschorner U, Kultgen PL, Rastan A. Treatment of femoropopliteal in-stent restenosis with paclitaxel-eluting stents. JACC Cardiovasc Interv. 2013;6:274-281.
45. Tielbeek AV, Rietjens E, Buth J, Vroegindeweij D, Schol FP. The value of duplex surveillance after endovascular intervention for femoropopliteal obstructive disease. Eur J Vasc Endovasc Surg. 1996; 12:145-150.
46. Spijkerboer AM, Nass PC, de Valois JC, Eikelboom BC, Overtoom TT, Beek FJ, Moll FL, Mali WP. Iliac artery stenoses after percutaneous transluminal angioplasty: Follow-up with duplex ultrasonography. J Vasc Surg. 1996;23:691-697.
47. Mewissen MW, Kinney EV, Bandyk DF, Reifsnyder T, Seabrook GR, Lipchik EO, Towne JB. The role of duplex scanning versus angiography in predicting outcome after balloon angioplasty in the femoropopliteal artery. J Vasc Surg. 1992;15:860-865.
48. Tosaka A, Soga Y, Iida O, Ishihara T, Hirano K, Suzuki K, Yokoi H, Nanto S, Nobuyoshi M. Classification and clinical impact of restenosis after femoropopliteal stenting. J Am Coll Cardiol. 2012;59:16-23.
49. Yeo KK, Malik U, Laird Jr. Outcomes following treatment of femoropopliteal in-stent restenosis: A single center experience. Catheter Cardiovasc Interv. 2011;78:604-608.
50. Wissgott C, Kamusella P, Andresen R. Treatment of in-stent reocclusions of femoropopliteal arteries with mechanical rotational catheters [in German]. Rofo. 2011;183:939-944.
51. Levy M TT, Kinlay S, Sobieszczyk P, Eisenhauer A. Endovascular brachytherapy as an adjunctive treatment for long segment lower extremity instent restenosis. Catheter Cardiovasc Interv. 2010;75:S93.
52. Duda SH, Bosiers M, Lammer J, Scheinert D, Zeller T, Oliva V, Tielbeek A, Anderson J, Wiesinger B, Tepe G, Lansky A, Jaff MR, Mudde C, Tielemans H, Beregi JP. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: Long-term results from the SIROCCO trial. J Endovasc Ther. 2006;13:701-710.
53. Lammer J, Bosiers M, Zeller T, Schillinger M, Boone E, Zaugg MJ, Verta P, Peng L, Gao X, Schwartz LB. First clinical trial of nitinol self-expanding everolimus-eluting stent implantation for peripheral arterial occlusive disease. J Vasc Surg. 2011;54:394-401.